Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14587732 | 0.92 | LMNA (0.51) | MAPK8PPARGMEN1KMT2ALMNA | |
| SCHEMBL14587614 | 0.91 | MAPK8 (0.44) | MAPK8PPARGMEN1KMT2ALMNA | |
| SCHEMBL14587619 | 0.89 | KCNH2 (0.49) | MAPK8PPARGMEN1KMT2ALMNA | |
| SCHEMBL14587615 | 0.89 | MAPK8 (0.53) | MAPK8PPARGMEN1KMT2ALMNA | |
| SCHEMBL14587706 | 0.88 | PPARG (0.48) | MAPK8PPARGMEN1KMT2ANTRK1 | |
| SCHEMBL14587705 | 0.88 | MEN1 (0.47) | MAPK8PPARGMEN1KMT2ANTRK1 | |
| SCHEMBL14587703 | 0.88 | MEN1 (0.47) | MAPK8PPARGMEN1KMT2ANTRK1 | |
| SCHEMBL5012144 | 0.86 | PPARG (0.52) | PPARGMEN1KMT2ALMNANTRK1 | |
| SCHEMBL14301500 | 0.86 | NTRK1 (0.41) | PPARGMEN1KMT2ANTRK1MAPK1 | |
| SCHEMBL14587736 | 0.86 | RAB9A (0.42) | PPARGNTRK1MAPK1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | MAPK8 1618/4885PPARG 706/4885MEN1 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.